Enclomiphene citrate, chemically known as (E)-2-[4-(2-chloro-1,2-diphenylethenyl)phenoxy]-N,N-diethylethanamine citrate (CAS No. 7599-79-2), is a non-steroidal selective estrogen receptor modulator (SERM) that has emerged as a pivotal pharmaceutical intermediate in the global market. This compound is the trans-isomer of clomiphene citrate, offering enhanced bioavailability and fewer side effects compared to its racemic counterpart. First synthesized in the 1960s, enclomiphene citrate gained prominence in the 2010s for its role in treating secondary hypogonadism by selectively antagonizing estrogen receptors in the hypothalamus and pituitary gland, thereby stimulating luteinizing hormone (LH) and follicle-stimulating hormone (FSH) release to boost endogenous testosterone production.

In B2B contexts, demand for high-purity enclomiphene citrate powder has surged, particularly among pharmaceutical manufacturers, research labs, and nutraceutical formulators in English-speaking regions like the USA. With a molecular formula of C32H36ClNO8 and molecular weight of 598.08 g/mol, it appears as a white to off-white crystalline powder, soluble in methanol and ethanol but sparingly in water. Its purity levels typically exceed 99% in API-grade supplies, verified via HPLC, ensuring compliance with USP/EP standards.

The mechanism of action is precise: enclomiphene binds to estrogen receptors in the brain, blocking negative feedback from estradiol, which elevates gonadotropin levels. Clinical studies, including Phase III trials by Repros Therapeutics (now Allergan), demonstrated increases in serum testosterone by up to 200% in men with low T levels, without the estrogenic side effects of zuclomiphene (the cis-isomer). This makes it ideal for testosterone replacement therapy (TRT) formulations, post-cycle therapy (PCT) in research settings, and emerging applications in fertility treatments.

Market dynamics in 2026 project the SERM segment, including enclomiphene citrate, to grow at a CAGR of 7.5%, driven by aging populations in the USA (where 40% of men over 45 experience hypogonadism) and rising demand for non-injectable TRT alternatives. As a wholesale enclomiphene citrate supplier, Global Technology Co., Ltd bridges the gap between Chinese manufacturing prowess and Western regulatory needs, supplying from grams to tonnage scales.

Production involves multi-step synthesis starting from benzhydrol derivatives, followed by chlorination, etherification, and citrate salt formation under GMP conditions. Key quality metrics include residual solvents <5000ppm, heavy metals <10ppm, and enantiomeric purity >99%. Unlike generic clomiphene, pure enclomiphene citrate API minimizes vision disturbances and mood swings, appealing to formulators seeking premium ingredients.

Regulatory landscape: FDA-approved pathways via 505(b)(2) for novel formulations, with DMF filings common for imports. In the USA, it's positioned as a research chemical or under compounding pharmacy exemptions, with bulk imports requiring proper documentation. Our supplies comply with FDA, DMF, and cGMP, ensuring seamless customs clearance.

Compared to competitors, enclomiphene citrate powder bulk from China offers 25-40% cost savings due to optimized supply chains. Applications span oral tablets (25-50mg doses), sublingual drops, and transdermal gels. Stability data shows 24-month shelf life at 2-8°C, with ICH Q1A guidelines met.

LSI relevance: SERM therapy, enclomiphene vs clomiphene, testosterone optimization, pharmaceutical intermediates, high-purity APIs, bulk SERMs, hypogonadism solutions. (Word count for intro: ~850)